Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02059408 · ClinicalTrials.gov registry record · NA
Screen-and-treat Program for Chronic Kidney Disease- High Risk Persons
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 1,819
- Enrollment target
NCT02059408: Completed NA study, sponsored by University of California, San Francisco.
NCT02059408 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 1,819 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02059408, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,819 participants
- Enrollment target
Study Summary
The overall hypothesis of this trial is that screening for chronic kidney disease, followed by education or treatment program will improve blood pressure control among hypertensive non-diabetic persons.
Primary Outcome
Change in blood pressure from enrollment to the end of the 12-month follow up period as a continuous outcome,
Interventions
- OTHER Screen-Educate
- OTHER Screen-Educate and Intensify Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,819 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-12 |
| Phase | NA |
What the finished NCT02059408 record still lists
NCT02059408 is an interventional study that assigns participants to a tested intervention. Its 1,819 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (30% higher).
The record links to 0 conditions, and to 2 interventions - of which Screen-Educate is the first listed.
NCT02059408 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02059408 about?
NCT02059408 is a clinical study titled "Screen-and-treat Program for Chronic Kidney Disease- High Risk Persons". The overall hypothesis of this trial is that screening for chronic kidney disease, followed by education or treatment program will improve blood pressure control among hypertensive non-diabetic persons.
What is the current status of trial NCT02059408?
This trial is currently completed. It is a NA study. The enrollment target is 1,819 participants. The study started on 2015-09. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02059408?
The interventions under investigation include: Screen-Educate (OTHER), Screen-Educate and Intensify Treatment (OTHER).
Who is sponsoring clinical trial NCT02059408?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02059408's enrollment target sits among peer trials
1,819 57th of 2000 higher than 1,944 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05897788 · 1,808 participants · NA
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
- NCT05935007 · 1,805 participants
Aveir DR Real-World Evidence Post-Approval Study
- NCT07104240 · 1,836 participants · NA
A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia